Show simple item record

dc.contributor.authorSud, Aen_US
dc.contributor.authorThomsen, Hen_US
dc.contributor.authorSundquist, Ken_US
dc.contributor.authorHoulston, RSen_US
dc.contributor.authorHemminki, Ken_US
dc.date.accessioned2017-09-21T09:05:49Z
dc.date.issued2017-05en_US
dc.identifier.citationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 35 (14), pp. 1584 - 1590en_US
dc.identifier.issn0732-183Xen_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/834
dc.identifier.eissn1527-7755en_US
dc.identifier.doi10.1200/jco.2016.70.9709en_US
dc.description.abstractPurpose Although advances in Hodgkin lymphoma (HL) treatment have led to improved disease-free survival, this has been accompanied by an increased risk of second cancers. We sought to quantify the second cancer risks and to investigate the impact of family history. Patients and Methods Using the Swedish Family-Cancer Project Database, we identified 9,522 individuals with primary HL diagnosed between 1965 and 2012. We calculated standardized incidence ratios and cumulative incidence of second cancer in HL survivors and compared the standardized incidence ratios of lung, breast, colorectal, and all second cancers in HL survivors with and without a site-specific family history of cancer. Interactions between family history of cancer and HL treatment were evaluated under additive and multiplicative models. Results Overall, the risk of a second cancer in HL survivors was increased 2.39-fold (95% CI, 2.29 to 2.53). The 30-year cumulative incidence of breast cancer in women diagnosed with HL at younger than 35 years of age was 13.8%. We observed no significant difference in cancer risk over successive time periods. The risk of all second cancers was 1.3-fold higher for HL survivors with a first-degree relative with cancer ( P < .001), with 3.3-fold, 2.1-fold, and 1.8-fold differences shown for lung, colorectal, and breast cancers, respectively. Moreover, a greater than additive interaction between family history of lung cancer and HL treatment was shown ( P = .03). Conclusion HL survivorship is associated with a substantive risk of a second cancer. Notably, the risk is higher in individuals with a family history of cancer. This information should be used to inform risk-adapted therapy and to assist in screening to reduce long-term morbidity and mortality in patients with HL.en_US
dc.formatPrint-Electronicen_US
dc.format.extent1584 - 1590en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectHumansen_US
dc.subjectHodgkin Diseaseen_US
dc.subjectLymphoma, Non-Hodgkinen_US
dc.subjectBreast Neoplasmsen_US
dc.subjectColorectal Neoplasmsen_US
dc.subjectLung Neoplasmsen_US
dc.subjectNeoplasms, Second Primaryen_US
dc.subjectGenetic Predisposition to Diseaseen_US
dc.subjectMedical History Takingen_US
dc.subjectIncidenceen_US
dc.subjectRisk Factorsen_US
dc.subjectFollow-Up Studiesen_US
dc.subjectAge Factorsen_US
dc.subjectSex Factorsen_US
dc.subjectTime Factorsen_US
dc.subjectAdolescenten_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectMiddle Ageden_US
dc.subjectChilden_US
dc.subjectChild, Preschoolen_US
dc.subjectSurvivorsen_US
dc.subjectSwedenen_US
dc.subjectFemaleen_US
dc.subjectMaleen_US
dc.subjectYoung Adulten_US
dc.titleRisk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-01-18en_US
rioxxterms.versionofrecord10.1200/jco.2016.70.9709en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2017-05en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJournal of clinical oncology : official journal of the American Society of Clinical Oncologyen_US
pubs.issue14en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics
pubs.publication-statusPublisheden_US
pubs.volume35en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamCancer Genomicsen_US
dc.contributor.icrauthorHoulston, Richarden_US
dc.contributor.icrauthorSud, Amiten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/